Accelerating drug development for Alzheimer's disease through the use of data standards

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 3 - Trang 273-283 - 2017
Jon Neville1, Steve Kopko2, Klaus Romero1, Brian Corrigan3, Bob Stafford1, Elizabeth LeRoy2, Steve Broadbent1, Martin Cisneroz4, Ethan Wilson5, Eric Reiman6, Hugo Vanderstichele7, Stephen P. Arnerić1, Diane Stephenson1
1Critical Path Institute, Tucson, AZ, USA
2CDISC, Austin, TX, USA
3Division of Pharmacometrics, Pfizer Global Research and Development, Groton, CT, USA
4College of Medicine, The University of Arizona, Tucson, AZ, USA
5Arizona State University, Tempe, AZ USA
6Banner Medical institute, Arizona State University, Phoenix, AZ, USA
7Biomarkable, bvba, Gent, Belgium

Tóm tắt

AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integration of clinical data sets and represent the essential foundation for regulatory endorsement of drug development tools. Such tools increase the potential for success and accuracy of trial results.MethodsThe development of the Clinical Data Interchange Standards Consortium (CDISC) AD therapeutic area data standard was a comprehensive collaborative effort by CDISC and Coalition Against Major Diseases, a consortium of the Critical Path Institute. Clinical concepts for AD and mild cognitive impairment were defined and a data standards user guide was created from various sources of input, including data dictionaries used in AD clinical trials and observational studies.ResultsA comprehensive collection of AD‐specific clinical data standards consisting of clinical outcome measures, leading candidate genes, and cerebrospinal fluid and imaging biomarkers was developed. The AD version 2.0 (V2.0) Therapeutic Area User Guide was developed by diverse experts working with data scientists across multiple consortia through a comprehensive review and revision process. The AD CDISC standard is a publicly available resource to facilitate widespread use and implementation.DiscussionThe AD CDISC V2.0 data standard serves as a platform to catalyze reproducible research, data integration, and efficiencies in clinical trials. It allows for the mapping and integration of available data and provides a foundation for future studies, data sharing, and long‐term registries in AD. The availability of consensus data standards for AD has the potential to facilitate clinical trial initiation and increase sharing and aggregation of data across observational studies and among clinical trials, thereby improving our understanding of disease progression and treatment.

Tài liệu tham khảo

10.1016/j.neuron.2014.10.038

10.1056/NEJMp1401444

10.1126/scitranslmed.aaf8590

10.1542/peds.2013-1504

10.1177/1740774512438980

10.1016/j.jalz.2015.06.1896

10.1016/j.jbi.2015.06.023

FDA, 2016, FDA‐Study Data Technical Conformance Guide v3.2.1.pdf. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

The Clinical Data Interchange Standards Consortium. CDISC vision and mission [Internet]. [cited 2016 Aug 15]. Available at:http://www.cdisc.org/system/files/all/CDISC‐4‐Pager_pages_web.pdf.

10.1016/j.jalz.2015.04.005

10.1016/j.jalz.2013.05.1761

Brumfield M., 2014, The Critical Path Institute: transforming competitors into collaborators, Nat Rev Drug Discov, 13, 785, 10.1038/nrd4436

10.2217/nmt.11.51

Stephenson D Brumfield M Romero K Woodcock J Zineh I Reiman EM et al. Alzheimer's and Parkinson's diseases face common challenges in therapeutic development: role of the precompetitive consortium coalition against major diseases [Internet]. J Alzheimers Dis Parkinsonism. Available at:http://www.omicsonline.org/open‐access/alzheimers‐and‐parkinsons‐diseases‐face‐common‐challenges‐in‐therapeutic‐development‐role‐of‐the‐precompetitive‐consortiumcoalition‐against‐major‐diseases‐2161‐0460‐1000183.php?aid=42374. Accessed May 12 2016.

CDISC.Study Data Tabulation Model (SDTM) [Internet].2017[cited 2017 Jan 26]. Available at:https://www.cdisc.org/standards/foundational/sdtm

CmapTools [Internet]. Florida USA: Cmap. Available at:http://cmap.ihmc.us/cmaptools/cmaptools‐download/. Accessed January 26 2017.

10.1016/j.jalz.2014.11.005

10.1186/alzrt269

10.1016/j.jalz.2011.03.008

10.1016/S1474-4422(14)70090-0

10.1016/j.jalz.2014.03.003

10.1016/j.jalz.2012.11.003

10.1016/j.jalz.2014.05.1756

10.1038/nm.2221

10.1016/j.neurobiolaging.2011.09.003

10.1016/S1474-4422(16)00070-3

European Medicines Agency.Qualification opinion of Alzheimer's Disease Novel Methodologies/Biomarkers for PET Amyloid Imaging (Positive/Negative) as a Biomarker for Enrichment for use in Regulatory Clinical Trials in Predementia Alzheimer's Disease.2012 Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125018.pdf ; 2012. Accessed May 9 2016.

10.1016/j.euroneuro.2011.08.003

10.1373/clinchem.2013.202937

10.1212/WNL.0000000000000809

10.1016/j.jalz.2011.07.004

10.1016/j.cca.2015.05.024

10.3233/JAD-150953

10.1016/j.jalz.2013.05.1769

10.1016/j.jalz.2015.05.006

10.1002/cpt.16

10.4088/JCP.13m08927

10.1001/jamaneurol.2014.803

10.3389/fpsyg.2015.01095

10.1038/nrneurol.2015.177

10.1016/j.jalz.2016.04.001

10.1097/WAD.0000000000000121

10.3233/JAD-160573

10.1016/j.jalz.2014.08.099

10.2967/jnumed.115.171595

Jack C.R., 2011, Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criteria for Alzheimer's disease, Alzheimers Dement, 7

10.1148/radiol.10100800

10.1038/nrd4462

10.1146/annurev.med.59.090506.155819

US Food and Drug Administration.Providing Regulatory Submissions In Electronic Format—Standardized Study Data Guidance for Industry.2014 Available at:http://www.fda.gov/downloads/drugs/guidances/ucm292334.pdf ; 2014. Accessed May 9 2016.

10.1002/cpt.136

10.2217/bmm.15.90

US Food and Drug Administration.Biomarker Letter of Support for use of CSF Analytes Ab1‐42 tau and phosphotau as Exploratory Prognostic Biomarkers for Enrichment in Clinical Trials in Alzheimer's Disease.2015 Available at:http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM439713.pdf ; 2015. Accessed May 9 2016.

10.1089/neu.2014.3861

Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 3

273-283

Thông tin tác giả